NCT05228470: Phase 2: MagnetisMM-8: Study Of Elranatamab (PF-06863135) Monotherapy in China RRMM
NCT05238311: Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135)
NCT05317416: Phase 3: Elranatamab Versus Lenalidomide in Patients With NDMM post ASCT - MagnetisMM-7
NCT05020236: Phase 3-MagnetisMM-5: Elranatamab (PF-06863135) Vs & Elranatamab/Dara VS Dara/Pom/Dex
NCT05139225: Phase 1: A Study of TTI-621 and TTI-622 in Combination With Daratumumab RRMM
NCT05090566: Phase 2 MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) + Anti-Cancer Tx RRMM
NCT05014412: Phase 1/2: Elranatamab in MM That Has Come Back or Has not responded - MagnetisMM-9
NCT04798586: Phase 1: MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Patients Myeloma
NCT04649359: Phase 2 - MagnetisMM-3: Elranatamab (PF-06863135) Monotherapy in relapsed Myeloma
NCT03530683: Phase 1: A Trial of TTI-622 in Patients With Advanced Hem. Malignancies (TTI-622-01)
NCT03269136: Phase 1 -PF-06863135 As Single Agent & with Immunomodulatory Agents In relapsed Myeloma
NCT02663518: Phase 1: A Trial of TTI-621 for Patients With Hematologic Malignancies and Solid tumors